A federal judge has issued an emergency order imposing a series of restrictions on a dog-breeding facility in Virginia owned by an Indianapolis-based company after regulators said the site was responsible for the deaths of hundreds of beagle puppies.
Unleashing innovation: 40th anniversary of Bayh-Dole Act celebrates law credited with improving lives around the world
The Bayh-Dole Act, marking its 40th anniversary, has contributed hundreds of billions of dollars to the U.S. gross domestic product and supported million jobs by unleashing the discoveries in America’s leading universities. But the landmark legislation now hailed as an engine of innovation and enterprise almost never came to pass.Read More
Indianapolis-based Eli Lilly and Company says it has asked the U.S. government to allow emergency use of an experimental antibody therapy based on early results from a study that suggested the drug reduced symptoms, the amount of virus, hospitalizations and ER visits for patients with mild or moderate COVID-19.
As the coronavirus began its deadly march through the world, two well-respected American doctors identified a possible but seemingly unlikely remedy: Pepcid, the heartburn medication found on drugstore shelves everywhere. There were no published data or studies to suggest its effectiveness against the novel coronavirus. But that didn’t stop the Trump administration from granting a $21 million emergency contract that is now the subject of whistleblower complaints.
Eli Lilly and Co. has won another patent-infringement lawsuit against a competitor who was preparing to launch an alternative form of the chemotherapy drug Alimta prior to its patent expiration in May 2022.
Indiana Supreme Court justices will hear oral argument next week in a dispute between a medical components company and one of its former employees after several other former employees left the company to take sales positions together elsewhere.
The former owner and CEO of Pharmakon Pharmaceuticals Inc. in Noblesville was sentenced Wednesday to 33 months in prison for manufacturing and selling drugs that were as much as 25 times more potent than they should have been.
An Indianapolis judge’s ruling that blocked an Indiana law effectively banning stem cell research derived from aborted fetal tissue was reversed by a divided 7th Circuit Court of Appeals panel Thursday. The 2-1 decision is a defeat for Indiana University researchers challenging the ban, and a dissenting judge questioned the state’s motivation and intent behind a law he said threatens IU research into potential treatments for Alzheimer’s disease and other disorders.